4 November 2026 in Cancer Research
Epigenetic dysregulation plays a vital role in the progression of endometrial cancer, yet targeted treatment options remain limited. In this study, we identified the histone acetyltransferase KAT5 as a therapeutic target in endometrial cancer. KAT5 was significantly overexpressed in endometrial cancer and correlated with poor patient outcomes. Silencing KAT5 inhibited endometrial cancer cell proliferation and tumor growth. KAT5-deficient endometrial cancer cells exhibited impaired cytoskeletal dynamics, leading to heightened DNA damage and increased micronuclei formation. The release of micronuclear DNA into the cytoplasm activated the cGAS–STING pathway, thereby amplifying proinflammatory immune responses. Mechanistically, KAT5 acetylated H2A.Z to transcriptionally activate Arp2/3 complex genes, promoting actin polymerization and chromosomal stability. Inhibition of Arp2/3 or depletion of its subunit ARPC5 replicated the effects of KAT5 loss, whereas restoring ARPC5 mitigated chromosomal instability and cGAS activation. In transplantation models of endometrial cancer cell lines and syngeneic murine Trp53−/−;Pten−/− endometrial cancer organoids, pharmacologic inhibition of KAT5 with NU9056 suppressed tumor progression and enhanced immune cell infiltration. NU9056 also induced Arp2/3 disruption, genomic instability, and cGAS–STING activation in patient-derived organoids from clinical endometrial cancer samples. Together, these findings highlight KAT5 as a promising therapeutic target in endometrial cancer that influences chromatin remodeling, cytoskeletal dynamics, and immune modulation. Significance: KAT5 is an oncogenic epigenetic driver of endometrial cancer that induces H2A.Z acetylation-mediated Arp2/3 activation to promote progression and immune evasion, providing a strong rationale for developing KAT5-targeted dual anti-tumor/immunotherapeutic strategies.